JP6444579B2 - Drug container - Google Patents

Description

  The present invention relates to a medicine container that contains a volatile medicine, and particularly belongs to the technical field of a structure in which the contained medicine is gradually diffused.

  Conventionally, as shown in FIG. 4, for example, a medicine container 3 including a tray-shaped container 1 that contains a volatile medicine A and a film 2 that covers an open portion of the container 1 is known. (For example, refer to Patent Document 1). The film 2 is made of a resin having a property of allowing a volatilized drug to permeate but not a volatilized drug to permeate. Moreover, the container 1 has translucency. Therefore, the remaining amount of the medicine A inside can be visually recognized from the outside of the container 1.

JP 2012-147715 A

  By the way, since the polymer used as the raw material of the film 2 has a crystal part and a non-crystal part, among the components of the drug A, particularly a solvent molecule may enter the non-crystal part of the polymer. When this happens, the volume of the polymer increases and the film 2 swells.

  The present inventors have discovered that swelling of the film 2 may be a problem. That is, in Patent Document 1, the drug A is colored and made available as an indicator so that the user can grasp the remaining amount of the drug A by making the container 1 long and vertically translucent. Yes. When the film 2 swells under such a premise configuration, the film 2 is slackened. Then, as shown in FIG. 4, a large amount of the medicine A inside accumulates under the influence of gravity, and the lower side of the film 2 swells outward from the container 1. This increases the lower volume compared to before the film 2 swells, so that it seems that the level of the drug A is lowered and the remaining amount of the drug is reduced even immediately after the start of use. Feel something is wrong. In addition, the method of decreasing the drug A is fast in the initial stage and slows toward the end, and the accuracy as an indicator cannot be ensured. Furthermore, when the container 1 is viewed from the front as shown in FIG. 5, there is also a problem that the color of the medicine becomes darker as it goes down, and the accurate remaining amount cannot be grasped.

  The present invention has been made in view of such a point, and the object of the present invention is to provide a residual drug when the drug in the translucent container is gradually diffused using the volatile drug transmitting member. It is to be able to grasp the amount accurately and without feeling uncomfortable.

  In order to achieve the above object, in the present invention, the swelling rate of the volatile drug transmitting member is set to a predetermined value or less.

The first invention contains a container made of colorless and transparent polyethylene terephthalate that contains a colored liquid medicine having volatility and makes the contained medicine visible.
In a medicine container provided with a volatile drug permeable member arranged so as to cover the open portion of the container, configured to pass a volatilized drug and not pass a non-volatile drug,
The solvent contained in the drug is
Methanol only ,
Ethanol only,
Methanol and ethanol only,
Methanol and / or ethanol;
Methanol, ethanol, 1-propanol, 1-decanol, 1-dodecanol (dodecyl alcohol), isobutyl alcohol (2-methylpropyl alcohol, isobutanol), isoamyl alcohol (3-methyl-1-butanol), 1-pentanol, 2-butyl-1-octanol, 2-ethylhexanol, 2-propanol, 2-heptanol, ethylene glycol (ethane-1,2-diol), propylene glycol (1,2-propanediol), 2-ethyl-1, 3-hexanediol (2-Ethyl-3-propyl-1,3-propanediol), 1,3-butanediol (b-butylene glycol), hexylene glycol (2-methyl-2,4-pentanediol), polyethylene Glico 300, polyethylene glycol 400, diethylene glycol, triethylene glycol (2,2′-ethylenedioxybis (ethanol)), tetraethylene glycol, dipropylene glycol, diisobutyl carbinol (2,6-dimethyl-4-heptanol), diacetone alcohol ( 4-hydroxy-4-methyl-2-pentanone, acetonyldimethylcarbinol), benzyl alcohol (phenylmethanol), 2-phenylethanol, 3-methyl-3-methoxy1-butanol (Solfit, 2-methoxyethanol) , Highsolve MC (ethylene glycol monomethyl ether), Highsolve DM (diethylene glycol monomethyl ether, 2- (2-Methoxyethyl) ) Ethanol), Hymol TM (triethylene glycol monomethyl ether, 2- [2- (2-Methoxyxy) ethoxy] ethanol), Hymol PM (polyethylene glycol monomethyl ether), Highsolv DB (diethylene glycol monobutyl ether, 2- (2 -Butoxyethyl) ethanol), Highsolve MP (propylene glycol monomethyl ether, 1-methoxy-2-propanol), Highsolve DPM (dipropylene glycol monomethyl ether, (2-methoxymethyloxy) -propanol), DOWANOL PM (propylene glycol monomethyl ether, 1) -Methoxy-2-propanol), DOWA OL DPM (dipropylene glycol methyl ether, (2-methoxymethyloxy) -propanol), DOWANOL TPM (tripropylene glycol monomethyl ether, 3- [3- (3-methoxypropoxy) propoxy] -1-propanol), DOWANOL PNP (propylene) Monopropyl ether, 1-propoxy-2-propanol), DOWANOL DPNP (dipropylene glycol monopropyl ether, 1- (1-methyl-2-propoxyxy) -2-propanol), DOWANOL PNB (propylene glycol monobutyl ether, 1- Ethoxy-2-propanol), DOWANOL DPNB (zip) Lopylene glycol monobutyl ether, (2-Methoxymethyl) -propanol, DOWANOL TPNB (Tripropylene glycol butyl ether), Seafosol MG (Cellosolve, ethylene glycol monoethyl ether, 2-Ethoxyethanol), Propylene glycol monoethyl ether (1-Ethoxy-2) -Propanol), ethylene glycol monoisopropyl ether (isopropyl cellosolve, 2-propoxyethanol), propyl cellosolve (2-propoxyethanol, ethylene glycol monopropyl ether), ethylene glycol monobutyl ether (butyloxytol, 2-butoxyethanol), isoper M, Isopar L , Isopar H, Isopar G, Solvesso 200, Solvesso 150, Pegasol 3040, Exol D130, only one mixed with at least one of isophorone and n-methylpyrrolidone,
The volatile drug permeable member is made of linear low density polyethylene having a swelling rate of 5% or less due to the solvent component.

  In other words, when the volatile drug permeable member swells upon contact with the solvent component of the drug, when the swelling rate exceeds 5%, the drug container is arranged so that the volatile drug permeable member extends vertically as described above. In this case, the user feels uncomfortable and cannot accurately grasp the remaining amount. In the present invention, since the volatile drug permeable member swells in the range of 5% or less, the amount of looseness of the volatile drug permeable member is sufficiently reduced, and the drug container is in such a posture that the volatile drug permeable member extends vertically. Even if it arrange | positions, it becomes possible to suppress the quantity which a chemical | medical agent accumulates below. As a result, the liquid level does not drop significantly even immediately after the start of use, the color of the drug does not appear to be significantly different between the upper and lower sides, and how the drug is reduced at the beginning and end of the period of use. There is no big difference between the two.

  According to the first invention, since the swelling rate of the volatile drug transmitting member is set to 5% or less, the remaining amount of the drug can be accurately grasped without feeling uncomfortable.

It is a longitudinal cross-sectional view of the chemical | medical agent container which concerns on embodiment of this invention. FIG. 2 is a view corresponding to FIG. 1 before using the medicine container. It is a front view of a medicine container. It is a longitudinal cross-sectional view of the conventional chemical | medical agent container. It is a front view of the conventional chemical | medical agent container.

  Hereinafter, embodiments of the present invention will be described in detail with reference to the drawings. It should be noted that the following description of the preferred embodiment is merely illustrative in nature, and is not intended to limit the present invention, its application, or its use.

  FIG. 1 is a longitudinal sectional view during use of the medicine container 3 according to the embodiment of the present invention, and FIG. 2 is a longitudinal sectional view before the medicine container 3 is used. The drug container 3 includes a tray-shaped container 1 and a volatile drug permeable film 2 (volatile drug permeable member) disposed so as to cover an open portion of the container 1. Before use, as shown in FIG. 2, the drug non-permeable sheet 4 is attached to the volatile drug permeable film 2.

  The container 1 has a plate shape as a whole, and includes a concave portion 1a serving as a space in which the medicine A is accommodated, and a flat extending plate portion 1b extending outward from the peripheral edge of the opening of the concave portion 1a. . The bottom surface 1c of the recess 1a is formed substantially flat, and the peripheral surface 1d forms an angle close to 90 ° with respect to the bottom surface 1c. The entire recess 1 a is open, and the entire open portion is covered with the volatile drug permeable film 2.

  In this container 1, the depth of the concave portion 1a is substantially uniform as a whole. However, the present invention is not limited to this, and a deep portion or a shallow portion may be formed partially. Further, the container 1 may have a rod-like or columnar elongated shape.

  Examples of the material of the container 1 include a colorless and transparent resin material such as polyethylene-terephthalate (PET). The container 1 can be obtained by hot press molding a plate material made of PET.

  The volatile drug permeable film 2 is made of a translucent resin material, and is configured to pass the volatilized drug and not pass the non-volatilized drug. The volatile drug permeable film 2 can be made of, for example, linear low density polyethylene (LLDPE). The resin material constituting the volatile drug permeable film 2 has a property of increasing its volume when the molecules of the solvent of the drug A enter the non-crystalline part, that is, a property of swelling.

  The drug-impermeable sheet 4 has a property of preventing the volatilized drug and the liquid drug from passing therethrough, and examples thereof include an aluminum film, a polyester film, a polyamide film, and a polyacetal film. The drug non-permeable sheet 4 is detachably attached in a state of being in close contact with the entire surface of the volatile drug permeable film 2 opposite to the side facing the recess 1a.

  The container 1 contains a liquid drug A having volatility. The medicine A contains, for example, at least an insecticide and a pest repellent, a coloring agent, and a solvent. The solvent is capable of dissolving an insecticide such as transfluthrin, a repellent, and a colorant, and the swelling rate of the volatile drug permeable film 2 is 5% or less, preferably 3 by the measurement method described later. % May be used as long as it can be set to% or less. The colorant is for coloring the drug A, and various dyes can be used. The color of the drug A is not particularly limited, but it is preferable that the drug A is colored so thin as to have translucency.

  The method for measuring the swelling rate of the volatile drug permeable film 2 is as follows, and the swelling rate measured by this measuring method is the swelling rate of the present invention.

  First, the volatile drug permeable film 2 is cut into a 5 cm × 5 cm square to produce a test piece. The thickness of the test piece is 70 μm. About 8 ml of the solvent is prepared, and the test piece is immersed in this solvent for 2 hours. Within this time, the molecules of the solvent enter the non-crystalline part of the volatile drug permeable film 2 and the volatile drug permeable film 2 swells. Swelling is saturated before 2 hours.

  Thereafter, the test piece is taken out from the solvent, the solvent adhering to the test piece is wiped off with a filter paper, and the weight of the test piece is measured. This measurement result is defined as Wa (g).

  The test piece after the weight measurement is left to stand in an atmosphere of 105 ° C. for 2 hours to be completely dried and the weight is measured again. This measurement result is defined as Wb (g).

  Then, the swelling ratio is calculated from the following formula.

  Swelling rate (%) = (Wa−Wb) / Wb × 100

  That is, when the solvent molecules enter the volatile drug permeable film 2, the volume of the volatile drug permeable film 2 increases, and this appears in the form of swelling. The more the solvent molecules enter, the more the volatile drug permeable film 2 swells, and the amount of solvent molecules entering the volatile drug permeable film 2 depends on the weight Wa of the test piece before drying. It can be obtained by subtracting the weight Wb after complete drying (after the solvent molecules escape from the test piece). By calculating the swelling rate based on this, an appropriate value that matches the swelling mechanism can be obtained.

  The swelling rate of the volatile drug permeable film 2 varies depending on the type of the solvent, and in this embodiment, a solvent in which the swell rate of the volatile drug permeable film 2 is 5% or less can be used. In general, the affinity between the resin material and the solvent can be determined from the SP value (solubility parameter), and it tends to be considered that the closer the SP value is, the more likely the swelling occurs. According to, it turns out that this is not necessarily the case.

  Examples of the solvent in which the swelling rate of the drug permeable film 2 is 5% or less include the following. For example, methanol, ethanol (swelling rate 0.00%), 1-propanol (swelling rate 2.27%), 1-decanol (swelling rate 4.73%), 1-dodecanol (dodecyl alcohol), isobutyl alcohol (2 -Methylpropyl alcohol, isobutanol) (swelling rate 1.57%), isoamyl alcohol (3-methyl-1-butanol) (swelling rate 1.78%), 1-pentanol (swelling rate 2.46%), 2-butyl-1-octanol (swelling rate 2.96%), 2-ethylhexanol (swelling rate 1.40%), 2-propanol (swelling rate 2.25%), 2-heptanol (swelling rate 3.15) %), Ethylene glycol (ethane-1,2-diol) (swelling rate 0.23%), propylene glycol (1,2-propanediol), 2-ethyl- 1,3-hexanediol (2-Ethyl-3-propyl-1,3-propandiol), 1,3-butanediol (b-butylene glycol), hexylene glycol (2-methyl-2,4-pentanediol) (Swelling rate 2.29%), polyethylene glycol 300, polyethylene glycol 400, diethylene glycol, triethylene glycol (2,2′-ethylenedioxybis (ethanol)), tetraethylene glycol, dipropylene glycol, diisobutyl carbinol (2,6- Dimethyl-4-heptanol), diacetone alcohol (4-hydroxy-4-methyl-2-pentanone, acetonyldimethylcarbinol), benzyl alcohol (phenylmethanol), 2 -Phenylethanol (swelling rate 1.96%), 3-methyl-3-methoxy 1-butanol (Solfit, 2-methoxyethanol), Hisolv MC (ethylene glycol monomethyl ether) (swelling rate 1.53%), Highsolve DM (diethylene glycol monomethyl ether, 2- (2-methoxyethyl) ethanol) (swelling ratio 1.55%), Hymor TM (triethylene glycol monomethyl ether, 2- [2- (2-methoxyethyl) ethoxy] ethanol) (swelling) 2.15%), Hymol PM (polyethylene glycol monomethyl ether) (swelling rate 1.59%), Highsolve DB (diethylene glycol monobutyl ether, 2- (2-Butoxyethylene) ether l) (swelling rate 2.78%), high-solve MP (propylene glycol monomethyl ether, 1-methoxy-2-propanol) (swelling rate 1.84%), high-solve DPM (dipropylene glycol monomethyl ether, (2-methoxymethylethy)) -Propanol) (swelling rate 2.42%), highsolve EPH (ethylene glycol monophenyl ether, 2-phenoxyethanol) (swelling rate 0.97%), DOWANOL PM (propylene glycol monomethyl ether, 1-methoxy-2-propanol) (Swelling rate 2.00%), DOWANOL DPM (dipropylene glycol methyl ether, (2-methoxymethylethyoxy) -propanol) (swelling 1.81%), DOWANOL TPM (Tripropylene glycol monomethyl ether, 3- [3- (3-Methoxypropoxy) propoxy] -1-propanol) (swelling rate 2.29%), DOWANOL PNP (propylene glycol monopropyl ether) , 1-Propoxy-2-propanol) (swelling rate 2.17%), DOWANOL DPNP (dipropylene glycol monopropyl ether, 1- (1-Methyl-2-propoxyxy) -2-propanol) (swelling rate 3.45) %), DOWANOL PNB (propylene glycol monobutyl ether, 1-Ethoxy-2-propanol) (swelling ratio 1.94%), DOWANOL DPNB (dipropylene glycol) NOBUTYL ETHER, (2-Methoxymethyl) -propanol) (swelling rate 3.95%), DOWANOL TPNB (tripropylene glycol butyl ether) (swelling rate 3.52%), Seafosol MG (cellosolve, ethylene glycol monoethyl ether, 2- Ethoxyethylene) (swelling rate 0.66%), propylene glycol monoethyl ether (1-Ethoxy-2-propanol) (swelling rate 1.79%), ethylene glycol monoisopropyl ether (isopropyl cellosolve, 2-propoxyethanol) (swelling rate) 1.59%), propyl cellosolve (2-propoxyethanol, ethylene glycol monopropyl ether) (swelling rate 1.00%), ethylene glycol Rumonobutyl ether (butyloxytol, 2-butoxyethanol) (swelling rate 2.07%), Highsolve MMM (ethylene glycol dimethyl ether, 1,2-dimethoxyethane) (swelling rate 4.23%), Highsolve MDM (diethylene glycol dimethyl ether, 2 -Methoxyethyl ether) (swelling ratio 3.41%), Highsolve MTM (triethylene glycol dimethyl ether, 2,5,8,11-Tetraoxadodecane Triglyme 1,2-bis (2-Methoxyxy) ether) (swelling ratio 3.35) %), Highsolve MTEM (tetraethylene glycol dimethyl ether, 2,5,8,11,14-Pentoxaxpentadecane, 1,11-Dimethox) -3,6,9-trioxaundecane (swelling rate 1.72%), high-solve MPM (polyethylene glycol dimethyl ether) (swelling rate 2.27%), high-solve EDE (diethylene glycol diethyl ether, 1,1'-Oxybis (2- ethoxy-ethane)) (swelling rate 4.31%), highsolve EDM (diethylene glycol ethyl methyl ether, -ethoxy-2- (2-methoxyethyl) ethane) (swelling rate 4.31%), highsolve BTM (triethylene glycol butyl) Methyl ether) (swelling rate: 4.49%), high-solve MDPOM (dipropylene glycol dimethyl ether, 1,5-Dimethyl-2-methyl-3-oxahexane) (swelling rate: 3.37% ), High Solve MTPOM (Tripropylene Glycol Dimethyl Ether), Isopar M, Isopar L, Isopar H, Isopar G, Solvesso 200, Solvesso 150, Pegasol 3040, Exol D130, Isophorone, n-methylpyrrolidone, Examide M100, Examide B100, etc. be able to. These solvents may be used alone or in combination of two or more.

  By using the said solvent, the swelling rate by the solvent of the volatile chemical | medical agent permeable film 2 can be set to 5% or less. It is more preferable to use a solvent in which the swelling rate of the volatile drug permeable film 2 is 3% or less. Further preferred is a solvent in which the volatile drug permeable film 2 has a swelling ratio of 2% or less.

  In this embodiment, the container 1 is made of PET, and the container 1 may be whitened depending on the solvent. In order to prevent the container 1 from being whitened, among the above solvents, Highsolv EPH, Highsolv MMM, Highsolv MDM, Highsolv MTM, Highsolv MTEM, Highsolv MPM, Highsolv EDE, Highsolv EDM, Highsolv BTM, Highsolv MDPOM, Highsolv MTPOM, Examide It is preferable to use a solvent other than M100 and Ecamide B100.

  Further preferred solvents are those having low odor because they are diffused around humans. Moreover, since the chemical | medical agent A will be lose | eliminated immediately if a transpiration | evaporation rate is too fast, the transpiration | evaporation rate of the grade which the chemical | medical agent A has for several dozen days or more is preferable, for example.

  The medicine A may contain, for example, insect repellents, fragrances, deodorants and the like, or may contain two or more thereof.

  The procedure for manufacturing the medicine container 3 having the above-described configuration is as follows. First, the medicine A is injected into the container 1, and the volatile medicine-permeable film 2 in which the medicine non-permeable sheet 4 is integrated is placed around the extending plate portion 1 b of the container 1. Glue over. At this time, since the solvent of the drug A touches the volatile drug permeable film 2, the molecules of the solvent enter the amorphous part of the volatile drug permeable film 2, and the volatile drug permeable film 2 swells.

  When using the medicine container 3 having the above configuration, the medicine non-permeable sheet 4 is peeled off from the volatile medicine permeable film 2. Since the volatile drug permeable film 2 is already swollen, it may become slightly loosened. However, since the swelling rate is 5% or less, the amount of looseness is sufficiently small.

  At the time of use, it is set as the attitude | position which hold | maintained the chemical | medical agent container 3 in the holder which is not illustrated, ie, the attitude | position which the volatile chemical | medical agent permeable film 2 extends up and down. In this state, the drug A in the container 1 is released from the volatile drug permeable film 2 and diffuses around the drug A in the container 1. Thereby, an insecticidal effect and a pest repellent effect can be obtained. Moreover, since the container 1 has translucency, the remaining amount of the medicine A can be easily grasped from the outside.

  At the time of use, the drug A tends to accumulate under the influence of gravity, but since the swelling rate of the volatile drug permeable film 2 is 5% or less and the slack amount of the volatile drug permeable film 2 is sufficiently small, It becomes difficult to accumulate below. Therefore, the liquid level of the medicine A does not significantly decrease immediately after the start of use, and it is difficult for the user to feel uncomfortable. Further, as shown in FIG. 3, since the medicine A hardly accumulates below, the color of the medicine A looks the same from the top to the bottom of the container 1. In addition, there is no significant difference in how the amount of medicine is reduced between the beginning and end of the period of use.

  That is, when the volatile drug permeable film 2 swells upon contact with the solvent component of the drug A, if the swelling rate exceeds 5%, the drug container 3 is in such a posture that the volatile drug permeable film 2 extends vertically. As shown in FIG. 4, the drug level drops and the user feels uncomfortable and the remaining amount can be accurately grasped even though it is immediately after the start of use as shown in FIG. Disappear.

  In this embodiment, since the swelling rate of the volatile drug permeable film 2 is set to 5% or less, the remaining amount of the drug A can be accurately grasped without feeling uncomfortable.

  If the swelling rate of the volatile drug permeable film 2 is set to 3% or less, the amount of slackness of the volatile drug permeable film 2 is further reduced. The color of A can be made substantially the same, and there is almost no difference in how the drug A is reduced between the initial stage and the end of the period of use.

  The above-described embodiment is merely an example in all respects and should not be interpreted in a limited manner. Further, all modifications and changes belonging to the equivalent scope of the claims are within the scope of the present invention.

  As described above, the medicine container according to the present invention can be used to diffuse, for example, insecticides, insect repellents and the like.

1 Container 2 Volatile drug permeable film (Volatile drug permeable member)
3 Drug container 4 Drug impermeable sheet A Drug

Claims (1)

A container made of colorless and transparent polyethylene terephthalate that contains a volatile colored liquid medicine and that makes the contained medicine visible,
In a drug container provided with a volatile drug permeable film arranged so as to cover the open part of the container, configured to pass the volatilized drug and not pass the non-volatilized drug,
The drug container is used in a posture in which the volatile drug permeable film extends in the vertical direction,
The solvent contained in the drug is
Methanol only ,
Ethanol only,
Methanol and ethanol only,
Methanol and / or ethanol, 1-propanol, 1-decanol, 1-dodecanol (dodecyl alcohol), isobutyl alcohol (2-methylpropyl alcohol, isobutanol), isoamyl alcohol (3-methyl-1-butanol), 1- Pentanol, 2-butyl-1-octanol, 2-ethylhexanol, 2-propanol, 2-heptanol, ethylene glycol (ethane-1,2-diol), propylene glycol (1,2-propanediol), 2-ethyl -1,3-hexanediol (2-Ethyl-3-propyl-1,3-propandiol), 1,3-butanediol (b-butylene glycol), hexylene glycol (2-methyl-2,4-pentanediol) ), Polyethylene Glycol 300, polyethylene glycol 400, diethylene glycol, triethylene glycol (2,2′-ethylenedioxybis (ethanol)), tetraethylene glycol, dipropylene glycol, diisobutyl carbinol (2,6-dimethyl-4-heptanol), diacetone alcohol (4-hydroxy-4-methyl-2-pentanone, acetonyldimethylcarbinol), benzyl alcohol (phenylmethanol), 2-phenylethanol, 3-methyl-3-methoxy1-butanol (Solfit, 2-methoxyethanol) ), Highsolve MC (ethylene glycol monomethyl ether), Highsolve DM (diethylene glycol monomethyl ether, 2- (2-Methoxy) thoxy) ethanol), Hymol TM (triethylene glycol monomethyl ether, 2- [2- (2-Methoxyxy) ethoxy] ethanol), Hymol PM (polyethylene glycol monomethyl ether), Highsolv DB (diethylene glycol monobutyl ether, 2- ( 2-Butoxyethyl) ethanol), High Solve MP (propylene glycol monomethyl ether, 1-Methoxy-2-propanol), High Solve DPM (dipropylene glycol monomethyl ether, (2-Methoxymethyl) -propanol), DOWANOL PM (Propylene glycol monomethyl ether) 1-Methoxy-2-propanol) DOWANOL DPM (dipropylene glycol methyl ether, (2-methoxymethyloxy) -propanol), DOWANOL TPM (tripropylene glycol monomethyl ether, 3- [3- (3-methoxypropoxy) propoxy] -1-propanol), DOWANol PN (Pwanol glycol) Monopropyl ether, 1-propoxy-2-propanol), DOWANOL DPNP (dipropylene glycol monopropyl ether, 1- (1-methyl-2-propoxyxy) -2-propanol), DOWANOL PNB (propylene glycol monobutyl ether, 1- Ethoxy-2-propanol), DOWANOL DP NB (dipropylene glycol monobutyl ether, (2-methoxymethyl) -propanol), DOWANOL TPNB (tripropylene glycol butyl ether), seafosol MG (cellosolve, ethylene glycol monoethyl ether, 2-Ethoxyethanol), propylene glycol monoethyl ether (1- Ethoxy-2-propanol), ethylene glycol monoisopropyl ether (isopropyl cellosolve, 2-propoxyethanol), propyl cellosolve (2-propoxyethanol, ethylene glycol monopropyl ether), ethylene glycol monobutyl ether (butyloxytol, 2-butoxyethanol), Isopar M, A Isopar L, Isopar H, Isopar G, Solvesso 200, Solvesso 150, Pegasol 3040, Exol D130, Isophorone and n-methylpyrrolidone are only one of those mixed ,
The said volatile chemical | medical agent permeable film consists of linear low density polyethylene whose swelling rate by the said solvent component is 5% or less, The chemical | medical agent container characterized by the above-mentioned.